Skip to main content
Explore URMC

Hong Zhang, M.D., Ph.D.

Contact Information

Phone Numbers

Appointment: (585) 341-6750

Office: (585) 341-6750

Fax: (585) 275-1531

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Radiation Oncology


It is a privilege to care for our patients. I am committed to providing personalized radiation treatment of the highest quality, as well as compassionate care. My areas of expertise include prostate and head and neck cancers.

Conditions I Treat:

- Prostate cancer
- Head and neck cancers
- Breast cancer
- Other cancers



  • Radiation Oncology - American Board of Radiology


PhD | Case Western Reserve University School of Medicine

MD | Yale New Haven Hospital

Post-doctoral Training & Residency

07/01/2002 - 06/30/2006
Residency in Radiation Oncology at University of Rochester Medical Center

06/01/2001 - 06/01/2002
Internship in Internal Medicine at Rochester General Hospital

06/01/1993 - 12/31/1994
Fellowship in Neuroscience at Case Western Reserve University School of Medicine

VIEW ALL expand_more


Civic Service Award, Us TOO Rochester
Sponsor: Us TOO Rochester

AAMC Mid-Career Woman Faculty Leadership Development Seminar 12/2017
Sponsor: AAMC

Health Care Achievement Awards--Health Care Innovation
Sponsor: Rochester Business Journal
Location: Rochester, NY

Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

Patient- and Family- Centered ICARE High Performance Award

2012 - 2017
Civic Service Award, Us TOO Rochester
Sponsor: Us TOO Rochester

Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

Patient- and Family-Centered ICARE High Performance Award
Sponsor: University of Rochester Medical Center

Upstate New York Society of Therapeutic Radiology and Oncology Fall Meeting Resident Presenter Award
Location: Syracuse, NY

ASTRO Translational Research in Radiation Oncology Symposium Travel Grant Award

Janet M.Glasgow Memorial Achievement Citations
Sponsor: Yale University School of Medicine
Location: New Haven, Connecticut

Clyde Swift Award for Outstanding Medical Student
Sponsor: Yale University School of Medicine
Location: New Haven, Connecticut

VIEW ALL expand_more

Clinical Trials

Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy

Lead Researcher: Hong Zhang

This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or slow the growth of prostate cancer cell growth by blocking the androgens. Abiraterone acetate blocks some of the enzymes needed for androgen production and may cause the death of prostate cancer cells that need androgens to grow. Prednisone may help abiraterone acetate work better by making tumor cells more sensitive to the drug. Adding apalutamide and abiraterone acetate with prednisone to the usual usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading or extend time without disease spreading compared to the usual approach.

View Study Details

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Lead Researcher: Hong Zhang

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with chemotherapy or alone after surgery in treating salivary gland tumors. PURPOSE: This randomized phase II/III trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery.

View Study Details


Journal Articles

Zhang H, Kang S, Ali N, Baran A, Bylund K, Gentile D, Previte G, Matloubieh A, Gray A, Marou N. "Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results." Advances in radiation oncology.. 2020 5(3):388-395. Epub 2020 Feb 21.

Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. "Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2019 Feb 0; 131:45-51. Epub 2018 Dec 28.

Hong Zhang, Chris Duecette, Hongmei Young, Sanjukta Bandyopadhyay, Craig Grossman, Jerome Jean Gilles, Edward Messing, Yuhchyau Chen. "Risk of Adverse Pathological Features for Intermediate Risk Prostate Cancer: Clinical Implication for Definitive Radiation Therapy" . International Journal of Clinical Oncology. 2019; .

Books & Chapters

Chapter Title: Breast Cancer
Book Title: Principles and Practice of Radiation Therapy
Author List: Uschold G; Zhang H
Edited By: Washington CM; Leaver D
Published By: Mosby Elsevier 2009




Radiation Oncology at Highland Hospital